Telitacicept named orphan drug in EU as myasthenia gravis therapy
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
Telitacicept safely and effectively eased disease activity in adults with primary Sjögren’s disease, according to data from a now-complete Phase 3 clinical trial conducted in China. Because the trial met its primary goal, developer Remegen plans to ask China’s regulator, the Center for Drug Evaluation of the National Medical Products Administration, to approve the drug, according […] The post Telitacicept shows promise for primary Sjögren’s in Phase 3 trial appeared first on Sjogre...| Sjogren's Disease News – The Web's Daily Resource for Sjogren's Disease News
The anti-inflammatory therapy telitacicept for myasthenia gravis was granted orphan drug status in the EU by the European Medicines Agency.| Myasthenia Gravis News
Vor Bio signed an exclusive license agreement to develop and market Remegen’s telitacicept for MG outside China, Hong Kong, Macau, and Taiwan.| Myasthenia Gravis News
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept for generalized myasthenia gravis.| Myasthenia Gravis News
